Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,064.20 +45.81 (+0.91%) Dow
38,225.66 +322.37 (+0.85%) Nasdaq
15,840.96 +235.48 (+1.51%) Bitcoin USD
59,302.48 +1,577.20 (+2.73%) CMC Crypto 200
1,270.55 -0.19 (-0.02%)
AMGN Oct 2024 290.000 put
| Previous close | 27.35 |
| Open | 27.35 |
| Bid | 23.50 |
| Ask | 25.80 |
| Strike | 290.00 |
| Expiry date | 2024-10-18 |
| Day's range | 27.35 - 27.35 |
| Contract range | N/A |
| Volume | |
| Open interest | 14 |
- Yahoo Finance Video
Amgen, DraftKings, Live Nation: Trending tickers
Shares of Amgen (AMGN) are soaring at Thursday's market close after reporting first quarter results, with revenue exceeding expectations. The biotechnology giant's revenue rose by 22% during the quarter. DraftKings (DKNG) also delivered a strong earnings report, surpassing analysts' estimates on both the top and bottom lines. Buoyed by this performance, the company raised its full-year outlook. Live Nation (LYV) topped revenue estimates in its first quarter earnings, although the company reported a loss of $0.53 per share. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
- Reuters
UPDATE 1-Amgen first-quarter profit dips 1%, revenue rises 22%
Amgen reported a slightly lower first-quarter profit on Thursday, citing higher operating and interest expense from its recent acquisition of rare disease drugmaker Horizon Therapeutics, partially offset by double-digit revenue growth. The biotechnology company's adjusted profit fell 1% to $3.96 per share, which still beat the average analyst estimate of $3.88 per share, according to LSEG data. The results were "essentially in-linish ... although not anything significant for the Street given that it is still early in the year," David Song, portfolio manager of the Tema Obesity & Cardiometabolic ETF said in an email.
ReutersAmgen 'encouraged' by weight-loss drug interim data, shares jump
(Reuters) -Amgen said on Thursday it was encouraged by the findings after completing an interim analysis of a mid-stage study of experimental weight-loss drug MariTide and will no longer develop its oral obesity candidate AMG786. Shares of Amgen surged up 13% in after hours trading. Investors are highly focused on Amgen's pipeline of experimental weight-loss drugs, and the company said it expects to have data from the Phase 2 MariTide trial late this year and is planning "for a comprehensive Phase 3 program across multiple indications."
